Quality Assurance and Quality Control in the Pathology Dept.

Similar documents
Quality assurance and quality control in pathology in breast disease centers

Present Role of Immunohistochemistry in the. Subtypes. Beppe Viale European Institute of Oncology University of Milan Milan-Italy

Breast Cancer Diversity Various Disease Subtypes Clinical Diversity

# Best Practices for IHC Detection and Interpretation of ER, PR, and HER2 Protein Overexpression in Breast Cancer

GOALS AND OBJECTIVES BREAST PATHOLOGY

Evolution of Pathology

Reporting of Breast Cancer Do s and Don ts

DIAGNOSIS. Biopsy, Pathology and Subtypes. Knowledge Summary

XXV Congreso de la Sociedad Española de Anatomía Patológica y División Española de la International Academy of Pathology

Quality Indicators - Anatomic Pathology- HSC/STC Jul-Sep 2 nd Qtr. Apr-Jun 1 st Qtr

Recent advances in breast cancers

Surgical Pathology Issues of Practical Importance

Question 1 A. ER-, PR-, HER+ B. ER+, PR+, HER2- C. ER-, PR+, HER2- D. ER-, PR-, HER2- E. ER-, PR+, HER2+

Optimal algorithm for HER2 testing

FAQs for UK Pathology Departments

Brief Formalin Fixation and Rapid Tissue Processing Do Not Affect the Sensitivity of ER Immunohistochemistry of Breast Core Biopsies

Minimizing Errors in Diagnostic Pathology

Histological Type. Morphological and Molecular Typing of breast Cancer. Nottingham Tenovus Primary Breast Cancer Study. Survival (%) Ian Ellis

Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Pathology. AGO e. V. in der DGGG e.v. sowie in der DKG e.v.

Kristen E. Muller, DO, Jonathan D. Marotti, MD, Vincent A. Memoli, MD, Wendy A. Wells, MD, and Laura J. Tafe, MD

Contemporary Classification of Breast Cancer

Barriers to Understanding

FISH mcgh Karyotyping ISH RT-PCR. Expression arrays RNA. Tissue microarrays Protein arrays MS. Protein IHC

CANCER. Clinical Validation of Breast Cancer Predictive Markers

Dr. dr. Primariadewi R, SpPA(K)

Molecular classification of breast cancer implications for pathologists. Sarah E Pinder

Papillary Lesions of the Breast

Breast Imaging: Multidisciplinary Approach. Madelene Lewis, MD Assistant Professor Associate Program Director Medical University of South Carolina

3/27/2017. Disclosure of Relevant Financial Relationships. Papilloma???

Q: How do you clinically code the N if the nodes are stated to be positive on mammogram/us or other imaging? No biopsy of nodes was done.

A Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast

Basement membrane in lobule.

Q&A. Fabulous Prizes. Collecting Cancer Data: Breast 4/4/13. NAACCR Webinar Series Collecting Cancer Data Breast

NordiQC External Quality Assurance in Immunohistochemistry

Estrogen Receptor, Progesterone Receptor, and Her-2/neu Oncogene Expression in Breast Cancers Among Bangladeshi Women

BREAST CANCER PATHOLOGY

Image guided core biopsies:

Your Guide to the Breast Cancer Pathology. Report. Key Questions. Here are important questions to be sure you understand, with your doctor s help:

What is the Oncotype DX test?

Breast cancer: Molecular STAGING classification and testing. Korourian A : AP,CP ; MD,PHD(Molecular medicine)

IBCM 2, April 2009, Sarajevo, Bosnia and Herzegovina

Department of Pathology, Loyola University Medical Center, Maywood, IL 60153, USA 2

Utility of Adequate Core Biopsy Samples from Ultrasound Biopsies Needed for Today s Breast Pathology

10/15/2012. Biologic Subtypes of TNBC. Topics. Topics. Histopathology Molecular pathology Clinical relevance

Welcome! HER2 TESTING DIAGNOSTIC ACCURACY 4/11/2016

Disclosures 5/27/2012. Outline of Talk. Outline of Talk. When Is LCIS Clinically Significant? Classic LCIS. Classic LCIS

Breast Cancer MultiDisciplinary Approach

Interpretation of Breast Pathology in the Era of Minimally Invasive Procedures

Version 2 of these Guidelines were drafted in response to published updated ASCO/CAP HER2 test Guideline Recommendations-

The Effect of Delay in Fixation, Different Fixatives, and Duration of Fixation in Estrogen and Progesterone Receptor Results in Breast Carcinoma

Product Introduction

Her-2/neu expression and its correlation with ER status and various clinicopathological parameters

NPQR Quality Payment Program (QPP) Measures 21_18247_LS.

Carcinoma mammario: le istologie non frequenti. Valentina Guarneri Università di Padova IOV-IRCCS

EBUS-FNAB: HOW TO OPTIMIZE YOUR CYTOLOGY SAMPLES, LHSC EXPERIENCE. Dr. Mariamma Joseph Division Head of Cytopathology LHSC and Western University

Clinica Medellin - Medellin, Colombia

Protocol for the Examination of Biopsy Specimens From Patients With Invasive Carcinoma of the Breast

San Donato Hospital - Azienda USL TOSCANA SUDEST Arezzo - Arezzo, Italy

Histopathology National Quality Improvement Programme Data Report 2015 Edition 3 created July 2016

Dyson Center for Cancer Care - Poughkeepsie, New York, United States of America

One Breast Cancer Annual Report

Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer.

Ductal Carcinoma in Situ. Laura C. Collins, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA

Case Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.

Quality Control and Assurance in Anatomic Pathology: The Moffitt Experience

Mamma Centrum / Zelený Pruh - Prague, Czech Republic

Morphological and Molecular Typing of breast Cancer

My Personalized Breast Cancer Worksheet

Breast Unit - University of Heidelberg - Heidelberg, Germany

Contents 1 The Windows of Susceptibility to Breast Cancer 2 The So Called Pre-Neoplastic Lesions and Carcinoma In Situ

ACRIN 6666 Therapeutic Surgery Form

Enterprise Interest None

ACCME/Disclosures. Diagnosing Mesothelioma in Limited Tissue Samples. Papanicolaou Society of Cytopathology Companion Meeting March 12 th, 2016

Adequate Core Biopsy Samples from Stereotactic Biopsies Needed for Today s Breast Pathology

System-wide Ownership Group: Allina Health Breast Program Committee. Hospital Division Quality Council: August 2018

Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer

RNA preparation from extracted paraffin cores:

Pathology Report Patient Companion Guide

HER2 status assessment in breast cancer. Marc van de Vijver Academic Medical Centre (AMC), Amsterdam

CPC 4 Breast Cancer. Rochelle Harwood, a 35 year old sales assistant, presents to her GP because she has noticed a painless lump in her left breast.

Educator Navigation Guide

Layered-IHC (L-IHC): A novel and robust approach to multiplexed immunohistochemistry So many markers and so little tissue

HOSPITAL MODELO - LA CORUÑA, Spain

Cork University Hospital - Cork, Ireland

Ki-67 is a biological tumor marker that reflects tumor

Jessa Hospital - Hasselt, Belgium

Civic Hospital of Sanremo ASL 1 Imperiese - Sanremo, Italy

Groote Schuur Academic Hospital - Cape Town, South Africa

Barlavento Medical Centre - Portimão, Portugal

PROTOCOL SENTINEL NODE BIOPSY (NON OPERATIVE) BREAST CANCER - PATHOLOGY ASSESSMENT

Salivary Gland FNA ATYPICAL : Criteria and Controversies

Quality in Control. ROS1 Analyte Control. Product Codes: HCL022, HCL023 and HCL024

Introduction 1. Executive Summary 5

National Center of Oncology - Yerevan, Armenia

Breast pathology. 2nd Department of Pathology Semmelweis University

Gaining New Insights Through IF Multiplexed Staining and Analysis. Tyna Hope, Ph.D. P.Eng Biomarker Imaging Research Laboratory October 5, 2017

Guven Hospital - Ankara, Turkey

Ritu Nayar, MD Professor and Vice Chair of Pathology Northwestern University, Feinberg School of Medicine Chicago, IL

University Clinical Center Banja Luka, Breast Center - Banja Luka, Bosnia and Herzegovina

HISTOPATHOLOGY. Introduction

Transcription:

Quality Assurance and Quality Control in the Pathology Dept. Judith Sandbank M.D. Pathology Assaf-Harofeh Medical Center ISRAEL jsandbank@asaf.health.gov.il 2 nd IBDC, 9 th February, 2012

Pathology as a black hole??

Unique subject Labor intensive Numerous steps Pre analytical Analytical Post analytical Cooperation with clinicians

Time to Tissue Fixation Estrogen receptor 0 min 4 hrs 8 hrs overnight J. Qiu et al. AJCP,2010;134:813-9

Estrogen Receptor Immunohistochemistry Normal acini Tumor cells

Problematic Staining Normal acini Tumor cells

Score 0 Score 2+ Score 1+ Score 3+ Her2 Immunohistochemistry

Time 0 2 hours

Time 0 4 hours

Her2 FISH/Under fixation effect Her2 FISH/Optimal result

What does pronged fixation do? J.A. Ibarra et al. AJCP 2010;134:594-596

Her2 IHC 2+ 24-48hrs in formalin One week in formalin

HER2 IHC 3+ 24-48hrs in formalin One week in formalin

Her2 standardized controls Score 0 Score 1 Score 3

fresh IHC on old and fresh TMA slides HER2 ER Ecadherin old fresh old M. Mirlacher et al, Mod. Pathol. 2004;17:1414-1420

So as you see Everything has got to be under control.

QA/QC should be implemented on all Diagnostic elements: Morphology Immunohistochemistry Molecular studies Genomics

Can we use one without the other? For instance go straight to genomics and skip the rest. Adenoid cystic carcinoma

Gene expression profiling of Breast cancer Adenoid cystic breast carcinoma is Basal-like Basal-like

However, the cancers within the basal like zone are heterogeneous: IDC NOS, high grade ILC high grade, pleomorphic Metaplastic, high grade Myoepithelial carcinoma High grade (oat-cell) neuroendocrine Apocrine Medullary Adenoid-cystic Metaplastic, low-grade Low grade adenosquamous Fibromatosis-like Poor prognosis Good prognosis

We have to work with hierarchal priorities.

Morphologic accuracy: Diagnosis Tumor size Grade LVI Lymph node status

Immunohistochemistry Hormone receptors Her2 receptor Ki67 And others

Molecular Testing and Profiling FISH Her2 Amplification Gene Expression assays: Luminal A, B Her2 positive Triple-Negative Basal-Like

Pre-analytical Time to fixation Method of fixation Time of fixation Method of tissue processing Specimen delivery Specimen identification Accession errors Clinical history adequacy Analytical Assay validation Equipment calibration Standard Laboratory Procedure Staff training assess. Antigen retrieval Test reagents Standard controls Automation Post-analytical Interpretation Image analysis Reporting QA procedures: -lab accreditation -Proficiency tests -pathologists

Predictive Biomarkers Immunohistochemistry: Fixation issues Internal validation/controls External validation of relevant antibodies: ER, PR, Her2, Ki67. Molecular studies (Her2-FISH/ CISH/SISH): Concordance with IHC, statistics External validation

Timeliness/Turn Around Time (TAT) Frozen sections. Cytology specimens. Core needle biopsies. Mammotomy specimens. Lumpectomy / mastectomy specimens. Special studies (IHC, FISH).

Completeness of report A full report should contain all the following: Demographic details. A comprehensive macroscopic description. Assignment of all paraffin blocks to specific locations. Diagnosis/Tumor grade/tumor size. Margin status. Receptor status (IHC, FISH). SLN / calnd (protocol)

Full report (cont.) : Correlation with previous cytology, CNB, FS results. Concordance of diagnosis with ancillary results. Additional pathology in the breast tissue. Templates / Summary checklists Make the writing of these very elaborate reports required today, easier to read by the clinicians.

And last but not least: The Availability of the Pathologist The multidisciplinary nature of the breast disease centers has taken the pathologist out of the laboratory into the clinical sphere where he belongs. The timely cross-talk with the radiologists, surgeons and oncologists enables To find out discrepancies as soon as possible. To learn and understand the different radiological, clinical and pathological setups

Thank you for your attention